Autoimmune Diseases  >>  Olumiant (baricitinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Olumiant (baricitinib) / Eli Lilly
NCT01185353 / 2010-022504-42: A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

Checkmark P2b Data (CRA - AHPA 2014)
Feb 2014 - Feb 2014: P2b Data (CRA - AHPA 2014)
Checkmark EWRR 2014 - Rheumatoid arthritis
Feb 2014 - Feb 2014: EWRR 2014 - Rheumatoid arthritis
Checkmark Rheumatoid arthritis - ACR/ ARHP 2013
More
Completed
2b
301
US, Europe, RoW
LY3009104, Janus Kinase (JAK)1/JAK2 Inhibitor, JAK1/2 Inhibitor, INCB028050, baricitinib, Placebo, Methotrexate
Eli Lilly and Company, Incyte Corporation
Arthritis, Rheumatoid
12/11
03/14
NCT00902486 / 2009-011206-42: INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs

Checkmark Data
Nov 2010 - Nov 2010: Data
Completed
2
127
US, RoW
INCB028050, Baricitinib, Placebo
Incyte Corporation
Rheumatoid Arthritis
06/10
07/10
JAHH, NCT02708095 / 2015-004404-35: A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

Checkmark Efficacy and safety data in patients with SLE at EULAR 2020
Jun 2020 - Jun 2020: Efficacy and safety data in patients with SLE at EULAR 2020
Checkmark Safety and efficacy data
Jul 2018 - Jul 2018: Safety and efficacy data
Completed
2
314
Japan, US, Europe, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Systemic Lupus Erythematosus
10/17
11/17

Download Options